Sign In
Buy MRK
$119.05
-1.73 (-1.43%)
At Close: Jun 12, 2026
Moderna, Merck's skin cancer vaccine shows sustained benefit after five years
06:25am, Tuesday, 20'th Jan 2026
Moderna and Merck said on Tuesday their experimental vaccine for a serious type of skin cancer, used in combination with Keytruda, reduced the risk of recurrence or death by 49% in a mid-stage trial.
Moderna & Merck Announce 5-Year Data for Intismeran Autogene in Combination With KEYTRUDA(R) (pembrolizumab) Demonstrated Sustained Improvement in the Primary Endpoint of Recurrence-Free Survival in Patients With High-Risk Stage III/IV Melanoma Following Complete Resection
06:00am, Tuesday, 20'th Jan 2026
At a median five-year pre-planned follow-up of the Phase 2b KEYNOTE-942/mRNA-4157-P201 study, intismeran autogene in combination with KEYTRUDA reduced the risk of recurrence or death by 49% (HR=0.510;
3 “Forever Stocks” to Hold When the Market Won't Sit Still
10:32am, Monday, 19'th Jan 2026
With so much volatility in the market, it's a good time for investors to consider stocks that they can hold for the long haul. These compounders don't have to make up a large part of your portfolio, b
Winners & Losers: The ETF Playbook to Glide Trump's Great Healthcare Plan
08:41am, Monday, 19'th Jan 2026
Trump's Great Healthcare Plan redraws healthcare winners and losers - here's how ETFs like IHE could benefit as middlemen face pressure.
Rep. Julie Johnson Sells Merck & Co., Inc. (NYSE:MRK) Shares
02:02am, Monday, 19'th Jan 2026
Representative Julie Johnson (D-Texas) recently sold shares of Merck and Co., Inc. (NYSE: MRK). In a filing disclosed on January 15th, the Representative disclosed that they had sold between $1,001 an
Bank Hapoalim BM Sells 10,100 Shares of Merck & Co., Inc. $MRK
03:48am, Sunday, 18'th Jan 2026
Bank Hapoalim BM cut its holdings in shares of Merck and Co., Inc. (NYSE: MRK) by 45.2% in the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchang
Amalgamated Bank Sells 9,994 Shares of Merck & Co., Inc. $MRK
03:13am, Sunday, 18'th Jan 2026
Amalgamated Bank lessened its holdings in Merck and Co., Inc. (NYSE: MRK) by 2.1% during the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional inves
Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields
08:40am, Friday, 16'th Jan 2026
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high
Why Merck's 32% Rally Isn't Enough to Change the Bearish View
09:31am, Thursday, 15'th Jan 2026
MRK is up over 32% in three months, but declining estimates, Keytruda's upcoming LOE and Gardasil declines keep the stock sell-rated.
Is Merck Stock A Trap At $110?
09:10am, Thursday, 15'th Jan 2026
Merck stock surged more than 10% in a month after management delivered a confidence shock on January 12th. They're now projecting that their next-generation drugs—treatments for cardiometabolic, res
Elevate Capital Advisors LLC Acquires New Stake in Merck & Co., Inc. $MRK
05:56am, Thursday, 15'th Jan 2026
Elevate Capital Advisors LLC bought a new position in Merck and Co., Inc. (NYSE: MRK) in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The ins
Conning Inc. Boosts Stock Position in Merck & Co., Inc. $MRK
05:18am, Thursday, 15'th Jan 2026
Conning Inc. lifted its holdings in shares of Merck and Co., Inc. (NYSE: MRK) by 1,059.9% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission
Will Keytruda Continue to Aid Merck's Top Line in Q4 Earnings?
10:35am, Wednesday, 14'th Jan 2026
Keytruda drives over half of MRK's pharma revenues, but softer Q3 sales put investor focus on whether the blockbuster drug can lift Q4 sales performance.
Merck Lifts Long-Term Revenue Target
12:34pm, Tuesday, 13'th Jan 2026
Merck (MRK) says it now sees up to $70 billion in new revenue opportunities by the mid-2030s, as it works to offset the expected loss of exclusivity for its blo
Merck & Co., Inc. (MRK) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
10:25pm, Monday, 12'th Jan 2026
Merck & Co., Inc. (MRK) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
